Vasculitis - Pipeline Review, H1 2016

  • ID: 3635577
  • Report
  • 100 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AnGes MG, Inc.
  • Coherus BioSciences, Inc.
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Panacea Biotec Limited
  • Sandoz International GmbH
  • MORE
Vasculitis - Pipeline Review, H1 2016

Summary

The report ‘Vasculitis - Pipeline Review, H1 2016’, provides an overview of the Vasculitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Vasculitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Vasculitis and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Vasculitis
- The report reviews pipeline therapeutics for Vasculitis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Vasculitis therapeutics and enlists all their major and minor projects
- The report assesses Vasculitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Vasculitis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Vasculitis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Vasculitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AnGes MG, Inc.
  • Coherus BioSciences, Inc.
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Panacea Biotec Limited
  • Sandoz International GmbH
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Vasculitis Overview

Therapeutics Development

Pipeline Products for Vasculitis - Overview

Pipeline Products for Vasculitis - Comparative Analysis

Vasculitis - Therapeutics under Development by Companies

Vasculitis - Therapeutics under Investigation by Universities/Institutes

Vasculitis - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Unknown Stage Products

Vasculitis - Products under Development by Companies

Vasculitis - Products under Investigation by Universities/Institutes

Vasculitis - Companies Involved in Therapeutics Development

AnGes MG, Inc.

ChemoCentryx, Inc.

Coherus BioSciences, Inc.

Epirus Biopharmaceuticals, Inc.

F. Hoffmann-La Roche Ltd.

GlaxoSmithKline Plc

Hemostemix Ltd

Johnson & Johnson

K-Stemcell Co., Ltd.

Panacea Biotec Limited

Pfizer Inc.

Sandoz International GmbH

Stempeutics Research Private Limited

Teijin Pharma Limited

Vasculitis - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

ACP-01 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

belimumab - Drug Profile

Product Description

Mechanism of Action

R&D Progress

beperminogene perplasmid - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CCX-168 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Drug to Target Mac-1 for Vasculitis and Glomerulonephritis - Drug Profile

Product Description

Mechanism of Action

R&D Progress

immune globulin (human) - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibodies to Antagonize GPR4 for Vascular Inflammation - Drug Profile

Product Description

Mechanism of Action

R&D Progress

PF-1355 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

rituximab biosimilar - Drug Profile

Product Description

Mechanism of Action

R&D Progress

rituximab biosimilar - Drug Profile

Product Description

Mechanism of Action

R&D Progress

rituximab biosimilar - Drug Profile

Product Description

Mechanism of Action

R&D Progress

rituximab biosimilar - Drug Profile

Product Description

Mechanism of Action

R&D Progress

sirukumab - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Stem Cell Therapy for Thromboangiitis - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Stempeucel - Drug Profile

Product Description

Mechanism of Action

R&D Progress

tocilizumab - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Vasculitis - Recent Pipeline Updates

Vasculitis - Dormant Projects

Vasculitis - Product Development Milestones

Featured News & Press Releases

Nov 25, 2015: GSK announces start of phase III study of sirukumab in Giant Cell Arteritis

Jun 01, 2015: Stempeutics Receives Orphan Drug Designation (ODD) in the European Union for its Novel Stem Cell Drug "Stempeucel" for the Treatment of Thromboangiitis Obliterans

Mar 23, 2015: Stempeutics Receives Advanced Therapy Medicinal Product (ATMP) Classification From European Medicines Agency (EMA) for its Novel Stem Cell Drug 'Stempeucel'

Dec 04, 2014: ChemoCentryx Granted EU Orphan Drug Designation for CCX168, an Orally Administered Complement C5a Receptor Inhibitor, for the Treatment of Microscopic Polyangiitis and Granulomatosis With Polyangiitis, Two Forms of ANCA-Associated Vasculitis

Jun 03, 2014: ChemoCentryx's CCX168, an Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation in ANCA-Associated Diseases by the FDA

Apr 03, 2013: GlaxoSmithKline Starts Phase III Study Of Benlysta In Patients With Vasculitis

Aug 17, 2012: Anges Announces Publication Of Long-Term Phase I/II Trial Data Of Collategene In Medical Journal

May 26, 2012: ChemoCentryx Presents Data on CCX168 At 49th European Renal Association-European Dialysis And Transplant Association Congress

Oct 17, 2011: ChemoCentryx Initiates Phase II Clinical Trial For CCX168 In Vasculitis

Mar 24, 2011: AnGes Publishes Results Of Collategene Study In International Angiology

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Vasculitis, H1 2016

Number of Products under Development for Vasculitis - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Comparative Analysis by Unknown Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Vasculitis - Pipeline by AnGes MG, Inc., H1 2016

Vasculitis - Pipeline by ChemoCentryx, Inc., H1 2016

Vasculitis - Pipeline by Coherus BioSciences, Inc., H1 2016

Vasculitis - Pipeline by Epirus Biopharmaceuticals, Inc., H1 2016

Vasculitis - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016

Vasculitis - Pipeline by GlaxoSmithKline Plc, H1 2016

Vasculitis - Pipeline by Hemostemix Ltd, H1 2016

Vasculitis - Pipeline by Johnson & Johnson, H1 2016

Vasculitis - Pipeline by K-Stemcell Co., Ltd., H1 2016

Vasculitis - Pipeline by Panacea Biotec Limited, H1 2016

Vasculitis - Pipeline by Pfizer Inc., H1 2016

Vasculitis - Pipeline by Sandoz International GmbH, H1 2016

Vasculitis - Pipeline by Stempeutics Research Private Limited, H1 2016

Vasculitis - Pipeline by Teijin Pharma Limited, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Vasculitis Therapeutics - Recent Pipeline Updates, H1 2016

Vasculitis - Dormant Projects, H1 2016

List of Figures

Number of Products under Development for Vasculitis, H1 2016

Number of Products under Development for Vasculitis - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Targets, H1 2016

Number of Products by Stage and Targets, H1 2016

Number of Products by Mechanism of Actions, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
AnGes MG, Inc.
ChemoCentryx, Inc.
Coherus BioSciences, Inc.
Epirus Biopharmaceuticals, Inc.
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline Plc
Hemostemix Ltd
Johnson & Johnson
K-Stemcell Co., Ltd.
Panacea Biotec Limited
Pfizer Inc.
Sandoz International GmbH
Stempeutics Research Private Limited
Teijin Pharma Limited
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll